Michael G. Aman, Ph.D.

Dr. Aman is a child psychologist and a Principal Investigator at the Ohio State University Nisonger Center. He was recently honored by the Academy of Mental Retardation with the Career Scientist Award for 2003.

Education

University of Windsor, Ontario, Canada
B.A. Psychology (1968)

University of Illinois, Champaign, IL
M.A. Child/Experimental Psychology (1972)

University of Auckland, New Zealand
Ph.D. Child/Experimental Psychology (1979)

Positions

• Member, NIMH Review Committee: Behavioral Science Track Award for Rapid Transition (B/START). January, 1999.
  
  
• Member, NIMH Review Committee: Special Emphasis Panel: "Research Career Development in Mental Disorders of Children." July, 1999; Rockville, MD.
  
  
• Member, NIMH Review Committee: Special Emphasis Panel: "Research Career Development in Mental Disorders of Children." June, 2001; Rockville, MD.
  
  
• Member, National Institute of Health Center for Scientific Review Special Emphasis Panel for STARRT Centers (Centers for Excellence in Autism Research). December, 2002.

Honors

• Academy on Mental Retardation: Career Scientist Award, May 2003.
  
  Editorial Boards:
• Journal of Child and Adolescent Psychopharmacology, 1990-present.
• American Journal on Mental Retardation, 1999 to present (Associate Editor, 1993-1998).
• Clinical Therapeutics, March 2002-Present.
• Journal of Intellectual and Developmental Disability, 1987-present.
• Journal of Behavioral Education, 1991-present.
• Research in Developmental Disabilities, 1980-present.
• Ad hoc reviewing for many other journals.
• Chair, Editorial Board, (2000, May).
• Expert Consensus Guideline Series: Treatment of Psychiatric and Behavioral Problems in Mental Retardation. American Journal on Mental Retardation (Special Issue), 105, 159-228.
  
• Member, Janssen Pediatric Psychiatry Advisory Board, June 2001, 2002, New York, NY.
  
• Co-Chair, MR/DD Advisory Board, sponsored by Janssen Pharmaceutica Products, LP, November, 2001, Chicago, IL.

Selected Peer Reviewed Publications (of 150)

Aman, M.G., Singh, N.N., Stewart, A.W. et al. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency,89, 485- 491.

Aman, M.G., Singh, N.N., Stewart, A.W. et al. (1985). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89, 492-502.

Aman, M.G., Werry, J.S., Paxton, J.W. et al. (1987). Effect of sodium valproate on psychomotor performance in children as a function of dose, fluctuations in concentration, and diagnosis. Epilepsia, 28, 115 124.

Aman, M.G., Singh, N.N., Turbott, S.H. (1987). Reliability of the Aberrant Behavior Checklist and the effect of variations in instructions. American Journal of Mental Deficiency, 92, 237 240.

Aman, M.G., Kern, R.A. (1989). Review of fenfluramine in the treatment of the developmental disabilities. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 549 565.

Aman, M.G., Teehan, C.J., White, A.J. et al. (1989). Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. American Journal on Mental Retardation, 93, 452 460.

Aman, M.G., Werry, J.S., Paxton, J.W. et al. (1990). Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type, and time of medication. Epilepsia, 31, 51 60.

Aman, M.G. (1991) Assessing psychopathology and behavior problems in persons with mental retardation: A review of available instruments. (DHHS Publication No. [ADM] 91 1712.) Rockville, MD: U.S. Department of Health and Human Services.

Aman, M.G., Marks, R.E., Turbott, S.H. et al. (1991). Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 246 256.

Aman, M.G., Marks, R.E., Turbott, S.H. et al. (1991). Methylphenidate and thioridazine in the treatment of intellectually subaverage children: Effects on cognitive motor performance. J. Am. Acad . Child Adoles. Psychiatry, 30, 816 824.

Aman, M.G., Kern, R.A., McGhee, D.E. et al. (1993). Fenfluramine and methylphenidate in children with mental retardation and ADHD: Clinical and side effects. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 851-859.

Aman, M.G., Werry, J.S., Paxton, J.W. et al. (1994). Effects of phenytoin on cognitive-motor performance in children as a function of drug concentration, seizure type, and time of medication. Epilepsia, 35, 172-180.

Aman, M.G., Burrow, W.H., & Wolford, P.L. (1995). The Aberrant Behavior Checklist-Community: Factor validity and effect of subject variables for adults in group homes. American Journal on Mental Retardation, 100, 283-292.

Aman, M.G., Van Bourgondien, M.E., Wolford, P.C. et al. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672-1681.

Aman, M.G., Wolford, P.L. (1995). Consumer satisfaction with involvement in drug research: A social validity study. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 940-945.

Aman, M.G., Pejeau, C., Wolford, P. et al. (1996). Four-year follow-up of children with mental retardation and ADHD. Research in Developmental Disabilities, 17, 417-432.

Aman, M.G., Tassé, M.J.,Rojahn, J. et al. (1996). The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities, 17,41-57.

Aman, M.G., Kern, R.A., Osborne, P. et al. (1997). Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: Clinical effects. American Journal on Mental Retardation, 101, 521-534.

Aman, M.G., Arnold L.E., Armstrong, S.C. (1999). Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 279-289.

Aman, M.G. Madrid, A. (1999). Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 253-263.

Werry, J.S., Aman, M.G. (1999). Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed.). New York: Plenum Press.

Aman, M. G., Arnold L. E., & Armstrong, S. C. (1999). Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 279-289.

Aman, M.G., Collier-Crespin, A., & Lindsay, R.L. (2000). Pharmacotherapy of disorders in mental retardation. European Child and Adolescent Psychiatry, 9, 98-107.

Arnold, L.E., Aman, M.G., Martin, A. et al. (2000). Assessment in autism multisite randomized clinical trials (RCT)s. Journal of Autism and Developmental Disorders, 30, 99-111.

Aman, M.G., Armstrong, S., Buican, B., & Sillick, T. (2002). Four-year follow-up of children with low intelligence and ADHD: A replication. Research in Developmental Disabilities, 23, 119-134.

Aman, M.G., De Smedt, G., Derivan, A., Lyons, B., Findling, R.L., & The Risperidone Disruptive Behavior Study Group. (2002). Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: A double-blind, placebo-controlled study. American Journal of Psychiatry, 159, 1337-1346.

Brown, E. C., Aman, M. G., & Havercamp, S. M. (2002). Factor analysis and norms on parent ratings with the Aberrant Behavior ChecklistCCommunity for young people in special education. Research in Developmental Disabilities, 23, 45-60 .

Research Units on Pediatric Psychopharmacology Autism Network (including Aman, M.G.) (2002). A double-blind, placebo-controlled trial of risperidone in children with autistic disorder. The New England Journal of Medicine, 347 (no.5), 314-321.3

Snyder, R., Turgay, A., Aman, M.G., Binder, C., Fisman, S., Carroll, A., & The Risperidone Conduct Study Group. (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1026-1036.

Aman, M.G., Langworthy, K.S., & Collier-Crespin, A. (in press). Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders.

Langworthy-Lam, K.L., Aman, M.G., & Van Bourgondien, M.E. (2002). Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology, 12, 311-321.

Aman, M.G., Armstrong, S., Buican, B., & Sillick, T. (2002). Four-year follow-up of children with low intelligence and ADHD: A replication. Research in Developmental Disabilities, 23, 119-134.

Aman, M.G., De Smedt, G., Derivan, A., Lyons, B., Findling, R.L., & The Risperidone Disruptive Behavior Study Group. (2002). Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: A double-blind, placebo-controlled study. American Journal of Psychiatry, 159, 1337-1346.

Brown, E. C., Aman, M. G., & Havercamp, S. M. (2002). Factor analysis and norms on parent ratings with the Aberrant Behavior ChecklistCCommunity for young people in special education. Research in Developmental Disabilities, 23, 45-60.

Langworthy-Lam, K.L., Aman, M.G., & Van Bourgondien, M.E. (2002). Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology, 12, 311-321.

Research Units on Pediatric Psychopharmacology Autism Network (including Aman, M.G.) (2002). A double-blind, placebo-controlled trial of risperidone in children with autistic disorder. The New England Journal of Medicine, 347 (no.5), 314-321.3

Snyder, R., Turgay, A., Aman, M.G., Binder, C., Fisman, S., Carroll, A., & The Risperidone Conduct Study Group. (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1026-1036.

Aman, M.G., Buican, B., & Arnold, L.E. (2003). Methylphenidate treatment in children with low IQ and ADHD: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology, 13, 27-38.

Aman, M.G., Lam, K.L., & Collier-Crespin, A. (2003). Prevalence and patterns of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders, 33, 527-534.

Arnold L.E., Vitiello, B., McDougle, C., Scahill, L., Shah, B., Gonzalez, N.M., Chuang, S., Davies, M., Hollway, J., Aman, M.G., Cronin, P., Koenig, K., Kohn, A.E., McMahon D.J., Tierney, E. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. Journal of American Academy of Child and Adolescent Psychiatry, 42, 1443-1450.

Esbensen, A.J., Rojahn, J., Aman, M.G., & Ruedrich, S. (2003). Development of an instrument assessing affective symptoms in individuals with mental retardation. Journal of Autism and Developmental Disorders, 33, 617-629.

Rojahn, J., Aman, M.G., Matson, J.L., Mayville, E. (2003). The Aberrant Behavior Checklist and the Behavior Problems Inventory: Convergent and divergent validity. Research in Developmental Disabilities, 24, 391-404.

Aman, M.G. (2004). Management of hyperactivity and other acting-out problems in patients with autism spectrum disorders, Seminars in Pediatric Neurology, 11 (3), 225-228.

Aman, M.G., Binder, C., & Turgay, A. (2004). Risperidone effects in the presence of psychostimulant medicine in children with ADHD and disruptive behavior disorders. Journal of Child and Adolescent Psychopharmacology, 14, 243-254.

Brown, E. C., & Aman, M. G., & Lecavalier (2004). Empirical classification of behavioral and psychiatric problems in children with mental retardation. American Journal on Mental Retardation, 109, 445-455

Aman, M.G. & Gharabawi, G. (2004). Treatment of behavior disorders in mental retardation: Report on transitioning to atypical antipsychotics with emphasis on risperidone. Journal of Clinical Psychiatry, 65, 1197-1210.

Aman, M.G., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K., King, B., Pearson, D.A., Gernsbacher, M.A., & Chez, M. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9, 36-47.

Findling, R.L., Aman, M.G., De Smedt, G., Derivan, A., Lyons, B., and the Risperidone Disruptive Behavior Study Group. (2004). A long-term open-label study of risperidone in children with severe disruptive behaviors and subaverage IQ. American Journal of Psychiatry 161, 677-684.

Flarakos, J., Luo, W., Aman, M., Svinarov, D., Gerber,N., & Vouros, P. (2004). Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry. Journal of Chromatography, 1026, 175-183.

Hollander, E., Phillips, A., King, B., Guthrie, D., Aman, M.G., Law, P., Owley, T., & Robinson, R. (2004). Impact of recent findings on study design of future autism clinical trials. CNS Spectrums, 9, 49-56.

Kutcher, S., Aman, M.G., Brooks, S.J., Buitelaar, J., van Daalen, E. Fegert, J., Findling, R.L., Fisman, S., Greenhill, L.L., Huss, M., Kusumaker, V., Pine, D., Taylor, E., Tyano, S. (2004). International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions. European Neuropsychopharmacology, 14, 11-28.

Lindsay, R.L., Leone, S., & Aman, M.G. (2004). Discontinuation of risperidone and reversibility of weight-gain in children with disruptive behavior disorders. Clinical Pediatrics, 43 (5) 437-444.
Martin, A., Scahill, L., Anderson, G.M., Aman, M., Arnold, L.E., McCracken, J., McDougle, C.M., Tierney, E., Chuang, S., Vitiello, B., and the Research Units on Pediatric

Psychopharmacology Autism Network (2004). Weight and Leptin Changes among Risperidone-Treated Youths with Autism: Six-Month Prospective Data. American Journal of Psychiatry, 161, 1125-1127.

Shultz, J. Aman, M.G., Kelbley, T., Wallace, C.L.,Burt, D.B., Primeaux-Hart, S., Loveland, K., Thorpe, L., Bogos, E.S., Timon, J., Patti, P., & Tsiouris, J.(2004). Evaluation of screening tools for dementia in older persons with mental retardation. American Journal on Mental Retardation, 109, 98-110.

Aman, M.G., Buitelaar,J., DeSmedt, G., Wapenaar, R., & Binder, C. (in press). Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: Pooled analysis of effects of risperidone. Journal of Child and Adolescent Psychopharmacology.

Aman, M.G., Lam, K.S.L., & Van Bourgondien, M.E. (In press). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology.

Lecavalier, L., Aman, M.G., Hammer, D., Stoica,W., & Matthews, G.L. (In press). Factor analysis of the Nisonger Child Behavior Rating Form in children with autism spectrum disorders. Journal of Autism and Developmental Disorders.

Lord, C., Wagner, A., Rogers, S., Szatmari, P., Aman, M., Charman, T., Dawson, G., Durand, V.M., Grossman, L., Guthrie, D., Harris, S., Kasari, C., Marcus, L., Murphy, S., Odom, S., Pickles, A., Shaw, E., Siegel, B., Sigman, M., Stone, W., Smith, T., & Yoder, P. (In press). Challenges in evaluating psychosocial interventions for autistic spectrum disorders. Journal of Autism and Developmental Disorders.

McDougle, C.J., Scahill, L., Aman, M.G., McCracken, J.T., Tierney, E.,Davies, M., Arnold, L.E., Posey, D.J., Martin, A., Ghuman, J.K., Shah, B., Chuang, S.Z., Swiezy, N.B., Gonzalez, N.M., Hollway, J., Koenig, K., McGough, J., Ritz, L., Vitiello, B. (In press). Risperidone for the core symptom domains of autism: Results from the RUPP Autism Network Study. American Journal of Psychiatry.

Vitiello, B., Aman, M.G., Scahill, L., McCracken, J.T., McDougle, C.J., Tierney, E., Davies, M., & Arnold, L.E. (In press). Research knowledge among parents of children participating in a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry.

Neef, N. A., Marckel, J., Ferreri, S. J., Bicard, D. F., Endo, S., Aman, M. G., Miller, K. M., Jung, S., Nist, L., & Armstrong, N. (In press). Assessment of impulsivity: A comparison of children with and without a diagnosis of ADHD. Journal of Applied Behavior Analysis.

Research Units on Pediatric Psychopharmacology (including M.G. Aman). (In press.) Risperidone treatment of autistic disorder: Longer term benefits and blinded discontinuation after six months. American Journal of Psychiatry.